Researchers at the University of Toledo have reported that gut bacteria engineered to produce the ACE2 protein can reduce blood pressure in animal models. The findings appear in Pharmacological Research, highlighting a novel approach to managing hypertension through the microbiome.
The study used Lactobacillus paracasei, a beneficial gut bacterium that was modified to secrete ACE2. In the experimental setup, untreated mice showed lower ACE2 activity and higher blood pressure, underscoring the protective role ACE2 can play in vascular health.
ACE2 is known for its part in allowing SARS-CoV-2 to enter cells and also for modulating the renin-angiotensin system, a key regulator of blood pressure across species, including humans. By boosting intestinal ACE2 levels, treated animals demonstrated a reduction in angiotensin II, a hormone that can elevate blood pressure by narrowing blood vessels. Notably, while ACE2 levels rose similarly in male and female subjects, the blood pressure decrease was observed predominantly in female rats. This gender difference provides important clues about how microbiome-based therapies might interact with host biology and informs future research directions.
The authors emphasize that the work bridges theory and practice, showing how engineered gut microbes could contribute to treating hypertension while potentially reducing reliance on conventional medications. They also suggest that the same strategy could be adapted to target other diseases linked to the microbiome, inflammation, or vascular function.
Hypertension remains a major risk factor for heart disease, stroke, and kidney problems. The study authors argue that altering the microbiota can influence health outcomes, marking a step forward in applying microbiome science to real-world medical care. The research team notes that ongoing work will explore safety, dosing, and long-term effects before any clinical use is considered.
Experts in the field point out that maintaining a healthy vascular system depends on multiple factors, including diet, physical activity, and genetic predisposition. The new approach adds a biological tool to the broader effort to prevent cardiovascular events by managing blood pressure through innovative microbiome interventions. As science progresses, researchers anticipate that personalized microbiome therapies could complement lifestyle strategies and existing drugs. [1]
Previous experts have discussed methods to improve vascular health in older adults, especially those over 47, emphasizing the importance of monitoring blood pressure, engaging in regular exercise, and adopting heart-healthy nutrition. The current work contributes a fresh perspective by exploring how gut microbes might be harnessed to support these goals. [2]